Just to clarify - the Company itself publicly confirmed via LInkedin that all four team members, including the CEO and CFO, attended BIO International in Boston. This is what they said: "Our team - Michael Thurn, Paul Field, Jeffrey Brown and Dan O'Connell - is looking forward to joining the global buotech community next week at BIO International Convention 2025 in Boston."This isn't about where someone might have gone or what they might have been doing - that kind of speculation only confuses things further. My concern isn't about people attending conferences. It's about prioritisation and transparency.
When a company is still under clinical hold, has provided no meaningful update for months and investor confidence is low, it's perfectly reasonable to question how management is allocating time and resources - especially while retail shareholders continue to wear the risk.
That is not trolling. That is accountability.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $81.23M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.0¢ | 16.5¢ | $31.74K | 191.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 6000 | 1 |
View Market Depth
| Last trade - 14.35pm 25/06/2025 (20 minute delay) ? |
| NUZ (ASX) Chart |